Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Letter to the Editor

Page Path

HOME
ARTICLE CATEGORY
Letter to the Editor

Letter to the Editor

Presence of liver fibrosis in chronic hepatitis B patients with varying serum hepatitis B virus DNA levels: Letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”

Jian Wang, Shaoqiu Zhang, Chuanwu Zhu, Yuanwang Qiu, Chao Wu, Rui Huang

Clin Mol Hepatol. 2025;31(1):e27-e30. Published online August 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0602

View: 461 Download: 29

Letter to the editor on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”

Meng-Che Wu, Hui-Chin Chang, Yi-Sheng Jhang, Shuo-Yan Gau

Clin Mol Hepatol. 2025;31(1):e13-e14. Published online September 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0682

View: 735 Download: 78

Letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”

Xiao-Song Li, Xi-Ping Shen, Hang Li

Clin Mol Hepatol. 2025;31(1):e15-e16. Published online September 12, 2024

DOI: https://doi.org/10.3350/cmh.2024.0784

View: 470 Download: 27

Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes

Meng-Yuan Miao, Jie-Qiong Lyu, Wei Jiang, Zhong-Yue Liu, Guo-Chong Chen

Clin Mol Hepatol. 2025;31(1):e35-e38. Published online September 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0719

View: 543 Download: 52

Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma

Binghua Li, Jingyuan Wen, Zhu Xu, Peng Yan, Bing Han, Decai Yu

Clin Mol Hepatol. 2025;31(1):e31-e34. Published online September 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0628

View: 620 Download: 83 Crossref: 1

Accountability in AI medicine: A critical appraisal of ChatGPT in patient self-management and screening

Jiawen Wang, Tian Xia

Clin Mol Hepatol. 2025;31(1):e1-e2. Published online September 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0769

View: 437 Download: 37

Comparison of the therapeutic effects of transarterial radioembolization and tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis

Hang Li, Hua Lu, Xi-Ping Shen, Xiao-Song Li

Clin Mol Hepatol. 2025;31(1):e3-e4. Published online October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0832

View: 481 Download: 39

Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults

Donghee Kim, Won Kim, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(1):e5-e7. Published online October 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0849

View: 414 Download: 26

Development of risk scores for prognosis prediction among patients with early-stage hepatocellular carcinoma

Xiping Shen, Ji Wu

Clin Mol Hepatol. 2025;31(1):e17-e18. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0794

View: 577 Download: 41

Letter regarding “Prevalence of clinically significant liver fibrosis in the general population”

Wei Feng, Qile Wang, Qingwang Ye

Clin Mol Hepatol. 2025;31(1):e21-e22. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0887

View: 512 Download: 22

Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs

Meng-Che Wu, Shih-Chi Yang, Shuo-Yan Gau

Clin Mol Hepatol. 2025;31(1):e19-e20. Published online October 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0906

View: 375 Download: 22

Urgent need for education on hepatocellular carcinoma surveillance among high-risk population in China

Lei Cai, Chao Li, Li-Yang Sun, Yong-Kang Diao, Ming-Da Wang, Tian Yang

Clin Mol Hepatol. 2025;31(1):e39-e43. Published online October 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0813

View: 433 Download: 42

Insights on risk score development: Considerations for early-stage hepatocellular carcinoma models

Zhanna Zhang, Gongqiang Wu

Clin Mol Hepatol. 2025;31(1):e8-e9. Published online November 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0958

View: 365 Download: 20

Grading severity of microvascular invasion in hepatocellular carcinoma: More details, more significance

Xiu-Ping Zhang, Fei-Fan Wu, Tian-Chen Zhang, Zhen-Qi Li, Ming-Gen Hu, Rong Liu

Clin Mol Hepatol. 2025;31(1):e10-e12. Published online November 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0986

View: 399 Download: 45

Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus

Xinpu Miao, Haidong Wu, Jinrong Xu, Wei Cheng

Clin Mol Hepatol. 2025;31(1):e23-e24. Published online November 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.1035

View: 291 Download: 13

The fibrosis-4 index for advanced liver fibrosis in NAFLD with T2DM: Half a loaf is better than no bread

Zeyu Wang, Dong Wan, Meidong Xu, Yong Jiang

Clin Mol Hepatol. 2025;31(1):e25-e26. Published online December 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0993

View: 361 Download: 32

Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed

Clin Mol Hepatol. 2024;30(4):982-986. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0691

View: 1087 Download: 56 Web of Science: 1 Crossref: 1

Differences in major adverse cardiovascular events of metabolic dysfunction-associated steatotic liver disease by race and ethnicity: Letter to the editor on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”

Hui-Chin Chang, Wen-Chieh Liao, Yi-Jen Fang, Shiu-Jau Chen, Shuo-Yan Gau

Clin Mol Hepatol. 2024;30(4):978-981. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0565

View: 1069 Download: 54 Crossref: 2

Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”

Yixuan Zhu, Xiaoyan Ma, Wenjing Ni, Yee Hui Yeo, Junping Shi, Jie Li

Clin Mol Hepatol. 2024;30(4):974-977. Published online July 4, 2024

DOI: https://doi.org/10.3350/cmh.2024.0417

View: 1501 Download: 74

Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy: Letter to the editor on “Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?”

Dorothy Cheuk-Yan Yiu, Huapeng Lin, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Ken Liu, Terry Cheuk-Fung Yip

Clin Mol Hepatol. 2024;30(4):970-973. Published online July 4, 2024

DOI: https://doi.org/10.3350/cmh.2024.0280

View: 1380 Download: 57

Metabolic dysfunction-associated fatty liver disease related hepatocellular carcinoma in China: An increasing problem: Letter to the edior on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”

Xiangyu Wu, Wenjing Ni, Qianqian Chen, Junping Shi, Jie Li

Clin Mol Hepatol. 2024;30(4):965-969. Published online June 18, 2024

DOI: https://doi.org/10.3350/cmh.2024.0386

View: 1808 Download: 85

Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease

Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(4):962-964. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0264

View: 1487 Download: 100 Web of Science: 1 Crossref: 4

Changing from NAFLD to MASLD: Cumulative incidence of gallstones between patients with NAFLD and those with MASLD in Asia

Shuhei Fukunaga, Tomoyuki Nakane, Michita Mukasa, Hidetoshi Takedatsu, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(4):959-961. Published online May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0233

View: 1377 Download: 69 Web of Science: 2 Crossref: 3

Functional cure of chronic hepatitis B encounters resmetirom

Nai-Bin Yang, Wai-Kay Seto, Ming-Hua Zheng

Clin Mol Hepatol. 2024;30(3):580-581. Published online April 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0301

View: 2177 Download: 100 Web of Science: 1 Crossref: 1

Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia

Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(3):577-579. Published online March 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0157

View: 2466 Download: 161 Web of Science: 6 Crossref: 4

Letter regarding “Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation”

Yun-Fan Liaw

Clin Mol Hepatol. 2024;30(2):269-271. Published online January 31, 2024

DOI: https://doi.org/10.3350/cmh.2024.0064

View: 2164 Download: 49 Web of Science: 1 Crossref: 1

Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):266-268. Published online January 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0028

View: 2298 Download: 62 Crossref: 1

Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD

Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):263-265. Published online January 18, 2024

DOI: https://doi.org/10.3350/cmh.2023.0557

View: 2868 Download: 140 Web of Science: 6 Crossref: 7

Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD

Shuhei Fukunaga, Michita Mukasa, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(1):121-123. Published online December 4, 2023

DOI: https://doi.org/10.3350/cmh.2023.0437

View: 2407 Download: 88 Web of Science: 7 Crossref: 8

Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”

Kuo Chao Yew, Sunny H. Wong, Vincent Wai-Sun Wong, Hazel H. Oon

Clin Mol Hepatol. 2024;30(1):118-120. Published online November 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0472

View: 2558 Download: 59 Web of Science: 2 Crossref: 1

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Video abstract

Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation
Impact Factor

14.0
First decision

07 Days

Publication after acceptance

03 Days

*Last 12 months

Viewed By 6194	MAFLD: How is it different from NAFLD?
Viewed By 5279	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5005	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4169	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 3943	Gut microbiome and metabolome signatures in liver cirrhosis-related complications

Cited By 272	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 225	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 155	MAFLD: How is it different from NAFLD?
Cited By 79	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 76	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis